Search for a command to run...
Brooks Laboratories Ltd. is underperforming its peers in terms of profitability and valuation metrics, primarily due to negative earnings and high PE ratio. However, it shows impressive revenue growth, suggesting potential for recovery. In contrast, companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. are strong performers with solid profitability and reasonable valuation, making them attractive for investors.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
BROOKS | ₹138.90 | ₹409.16Cr | 134.02 | -24.92% | 0.08 |
SUNPHARMA | ₹1,563.35 | ₹3,75,099.26Cr | 87.59 | 17.60% | 0.04 |
DIVISLAB | ₹6,091.05 | ₹1,61,698.50Cr | 73.20 | 16.46% | - |
CIPLA | ₹1,587.60 | ₹1,28,217.27Cr | 23.73 | 22.77% | 0.01 |
TORNTPHARM | ₹3,581.55 | ₹1,21,215.77Cr | 61.53 | 24.28% | 0.57 |
DRREDDY | ₹1,280.30 | ₹1,06,835.27Cr | 15.50 | 26.86% | 0.07 |
MANKIND | ₹2,518.95 | ₹1,03,926.59Cr | 55.18 | 28.38% | 0.02 |